Emerging Therapies for CML: ENLIVEN-01 Shows Promise in Early Trials

26 Visioni

Grazie! Condividilo con i tuoi amici!

Non hai gradito questo video. Grazie per il feedback!

Published Jul 4, 2025

In this segment, Dr. Andreas Hochhaus, a leading figure in oncology and chronic myeloid leukemia (CML) research, discusses the exciting potential of ENLIVEN-01, a new drug under investigation for chronic myeloid leukemia treatment. Despite decades of progress in managing CML, challenges like cml drug resistance and persistent BCR-ABL mutations, including the difficult T315I mutation, continue to limit the path toward a true chronic myeloid leukemia cure.

Dr. Hochhaus explains how ENLIVEN-01, an innovative tyrosine kinase inhibitor, stands out from traditional tyrosine kinase inhibitors used in cml treatment. With unique properties that reduce off-target effects and improve tolerability, this drug shows promise in early data from a phase I clinical trial. Particularly for patients with advanced disease or resistance, such as those needing blast phase CML treatment, new therapies like ENLIVEN-01 offer hope for better outcomes and quality of life.

What you’ll learn in this video:
▶ Why ENLIVEN-01 could redefine chronic myeloid leukemia treatment strategies
▶ How ENLIVEN-01 targets resistant forms of myeloid chronic leukemia driven by BCR-ABL mutations
▶ The importance of the T315I mutation in driving cml drug resistance
▶ Differences between ENLIVEN-01 and earlier tyrosine kinase inhibitors
▶ Early results from the ongoing phase I clinical trial and implications for future leukemia care

This conversation is crucial for anyone interested in the evolving field of chronic myelogenous leukemia, new approaches in leukemia research, and the ongoing search for a chronic myeloid leukemia cure.

#chronicmyeloidleukemia #CML #leukemia #oncology #ENLIVEN01 #BCRABL #tyrosinekinaseinhibitors #T315I #drandreashochhaus #mdnewsline